Breaks Categories: News

ThursdaySep 30, 2021 10:23 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Doses First Group of Patients in Potentially Pivotal Trial

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”), today announced the dosing of the first patients in its Berubicin clinical development program for the treatment of recurrent glioblastoma multiforme (“GBM”), one of the most aggressive types of brain cancer. According to the update, further patient enrollment, randomization and dosing is currently underway as well as a robust lineup of globally located clinical sites, which are advancing toward activation and enrollment. “As one of the most aggressive, deadly and treatment-resistant cancers that…

Continue Reading

WednesdaySep 29, 2021 10:43 am

BioMedNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Announces Beta Launch of MiBoKo

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced the beta launch of MiBoKo, a new metabolic health program utilizing a noninvasive glucose sensor along with an AI mobile application. According to the update, Nemaura’s Chief Executive Officer Dr. Faz Chowdhury will discuss MiBoKo in more detail during his corporate presentation scheduled for today, Sept. 29, 2021, at 11:10 a.m. ET during the Benzinga Healthcare Small Cap Conference. Investors can access the presentation by registering for the conference at https://ibn.fm/tbmt0. “A person’s response to…

Continue Reading

TuesdaySep 28, 2021 1:23 pm

BioMedNewsBreaks – RYAH Group Inc. (CSE: RYAH) Initiates Pilot Program with Four 20 Pharma in Germany

RYAH Group (CSE: RYAH) today announced that it has completed an initial shipment of its proprietary RYAH Smart Dry Herb Inhalers for use in a pilot study to be conducted by Four 20 Pharma GmbH, a leading manufacturer, wholesaler and importer of medical cannabis and medical devices. The study is being conducted in preparation for a wider distribution strategy for the RYAH Smart Dry Herb Inhaler and data analytics platform in the German market. Four 20 is expected to sponsor the launch of an observational study using the RYAH inhalers in order to collect accurate patient feedback on consumption of…

Continue Reading

TuesdaySep 28, 2021 11:25 am

BioMedNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) to Present at Benzinga Healthcare Small Cap Conference

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE”), a leader in advanced proprietary technology and research in psychedelics, today announced that its CEO and President Kelsey Ramsden will present and participate in one-on-one investor meetings at the Benzinga Healthcare Small Cap Conference. The event is scheduled to be held virtually on Sept. 29-30, 2021, with Ramsden’s presentation to begin at 4:00 p.m. ET on Wednesday, Sept. 29. Interested parties should visit https://ibn.fm/Wpkw4 to register for the event. In addition, the company announced it has granted a total of 10,000 stock options to certain employees pursuant to the terms…

Continue Reading

MondaySep 27, 2021 2:37 pm

BioMedNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) Announces Launch of the ‘Desire Project’

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE”), a leader in advanced proprietary technology and research in psychedelics, today unveiled its “Desire Project,” a clinical research program focused on the treatment of female hypoactive sexual desire disorder with MDMA-assisted psychotherapy. According to the update, the research program will mark the first psychedelic-based treatment program targeted at addressing what is clinically known as Hypoactive Sexual Desire Disorder (“HSDD”), a common sexual disorder characterized by persistent low sexual desire and emotional distress not attributable to an existing medical condition or relationship issue. Current estimates indicate that HSDD affects 10% of…

Continue Reading

MondaySep 27, 2021 12:34 pm

BioMedNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Enters Strategic Commercial Agreement with UK Licensee

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced its entry into a global commercial contract with MySugarWatch DuoPack Limited (“MSW-DP”). Under the agreement, the continuous glucose monitor (“CGM”) and sensors will be provided as duo packs with prescription only medicines that are widely prescribed for people with type 2 diabetes. MSW-DP has been granted global rights to the sugarBEAT(R) non-invasive CGM devices and sensors, to be provided solely as duo packs with these medicines, under the terms of the agreement, which Nemaura will…

Continue Reading

FridaySep 24, 2021 12:54 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Release FY 2021 Financial Report and Corporate Update

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing and clinical development of rare cannabinoids, has released its financial results and corporate update for FY 2021. In addition, the company announced a conference call and webcast, in which company leadership will discuss the report. Interested parties can access a replay of the webcast for 90 days. Corporate highlights of the report include the definitive agreement the company entered to acquire BayMedica Inc., a private company specializing in the manufacture and commercialization of rare cannabinoids; the announcement that INM’s IntegraSyn(TM) cannabinoid manufacturing approach had achieved a level of 2g/L cannabinoid yield,…

Continue Reading

ThursdaySep 23, 2021 9:54 am

BioMedNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Forms Medical Consortium to Advance OSA Technology

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild to moderate obstructive sleep apnea (“OSA”), today announced the official formation of the Vivos Medical Consortium. According to the update, this physician working group, led by Drs. Clete Kushida of Stanford University and Cecilia Wu of the University of Alberta, will collaborate to advance Vivos’ OSA technology capabilities. “Every specialty in medicine deals with the negative impact of obstructive sleep apnea in some way, with the end stage of untreated sleep apnea including diminished quality of life,…

Continue Reading

WednesdaySep 22, 2021 2:26 pm

BioMedNewsBreaks – RYAH Group Inc. (CSE: RYAH) to Present at Wall Street Reporter’s ‘Next Super Stock’ Livestream Conference

RYAH Group (CSE: RYAH) today announced that its Chief Executive Officer Gregory Wagner will be presenting at Wall Street Reporter's "Next Super Stock" livestream conference on Thursday, Sept. 23, 2021. The online event is expected to give the investment community and existing shareholders an opportunity to interact in real time with Wagner and learn about the company and its operations. Wagner’s presentation is scheduled to begin at 1:00 ET on the day of the conference, during which he will highlight RYAH’s experience and mission, and, time permitting, open the floor for questions. Interested parties should visit https://ibn.fm/K0MtA to ensure access…

Continue Reading

WednesdaySep 22, 2021 2:08 pm

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Submission of IND Application for Eating Disorders Clinical Trial

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, has submitted an Investigational New Drug ("IND") application to the U.S. Food and Drug Administration ("FDA"). The clinical trial is designed to evaluate the efficacy of TRYP’s clinical candidate, TRP-8802, for the treatment of patients with eating disorders. TRYP is working with Jennifer Miller, MD, from the University of Florida, to conduct the trial as well as evaluate its oral formulation of synthetic psilocybin, TRP-8802, in combination with psychotherapy. The IND application outlines specifics in regard to the safety of…

Continue Reading